Photo from Memorial Sloan Kettering Radiation Oncology/X
Jun 7, 2024, 20:40
Secondary analysis of a prospective, phase II RCT for metastatic HNSCC – Memorial Sloan Kettering Radiation Oncology
Memorial Sloan Kettering Radiation Oncology shared on X:
“New from Drs James Janopaul-Naylor and Sean McBride:.
This secondary analysis of a prospective, phase II RCT for metastatic HNSCC (nivolumab +/− SBRT) found no significant impacts on efficacy and toxicity of treatment time-of-day/circadian rhythm.”.